NCT00001446View on ClinicalTrials.gov

A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 30, 1995

Study Completion Date

July 31, 2001

Conditions
Prostatic Neoplasm
Interventions
DRUG

thalidomide

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00001446 - A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter